Lamivudine/Zidovudine Arrow

Lamivudine and Zidovudine, the active ingredients in Lamivudine/Zidovudine Arrow, are nucleoside reverse transcriptase inhibitors presented as an oral tablet for the treatment of HIV‑1 infection in adults and children. The combination blocks viral replication, helping to restore immune function and reduce disease progression.

GNH USA supplies Lamivudine/Zidovudine Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is available for bulk and individual dispensing.

Lamivudine/Zidovudine is used in antiretroviral therapy targeting HIV‑1 replication.

- HIV‑1 infection (adults): reduces plasma viral load and helps restore CD4+ T‑cell counts. - HIV‑1 infection (children): improves virologic control and supports immune recovery. - Prevention of mother‑to‑child transmission of HIV: used as part of a regimen to lower transmission risk.

Adverse reactions may occur with Lamivudine/Zidovudine therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness or weakness. - Anemia: reduction in hemoglobin levels. - Neutropenia: lowered neutrophil count. - Diarrhea: loose stools, often self‑limiting.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance requiring urgent care. - Hepatic steatosis: fatty liver disease that can progress to failure. - Bone marrow suppression: pancytopenia or severe anemia. - Hypersensitivity reactions: rash, fever, or organ involvement. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe anemia: requiring transfusion or medical intervention.

Use of Lamivudine/Zidovudine requires careful clinical monitoring.

- Assess renal function: adjust therapy in patients with impaired kidney function. - Monitor hematologic parameters: watch for anemia and neutropenia during treatment. - Screen for hepatitis B infection: risk of reactivation exists. - Avoid in patients with known hypersensitivity to nucleoside reverse transcriptase inhibitors. - Pregnancy considerations: weigh maternal benefits against potential fetal risks. - Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Lamivudine/Zidovudine may interact with several concomitant medicines.

Major Interactions (Avoid): - Didanosine: increased risk of peripheral neuropathy. - Stavudine: additive mitochondrial toxicity. - Alcohol: heightened potential for liver toxicity.

Moderate Interactions (Monitor Closely): - Protease inhibitors: may raise zidovudine plasma concentrations. - Non‑nucleoside reverse transcriptase inhibitors (efavirenz, nevirapine): can affect lamivudine levels. - Warfarin: possible alteration of INR requiring closer monitoring.